Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin

Journal of Pharmaceutical Sciences

Volumn 95, Issue 2, 2006, Pages 256-267

  Charman, Susan A ^a   Perry, Christine S ^a   Chiu, Francis C K ^a   McIntosh, Kylie A ^a   Prankerd, Richard J ^a   Charman, William N ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Complexation; Cyclodextrins; Distribution; Pharmacokinetics; Renal clearance

Indexed keywords

ANTIMALARIAL AGENT; BETA CYCLODEXTRIN DERIVATIVE; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CYCLODEXTRIN; GLUCOSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISSOCIATION; DRUG FORMULATION; ISOTHERMAL TITRATION CALORIMETRY; KIDNEY CLEARANCE; MALARIA; MALE; MOLECULAR INTERACTION; NONHUMAN; RAT;

EID: 32644434566     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20534     Document Type: Article

References (25)

1. Sachs J, Malaney P. 2002. The economic and social burden of malaria. Nature 415:680-685.
2. Ridley RG. 2002. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 415:686-693.
3. Cumming JN, Ploypradith P, Posner GH. 1997. Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: Mechanism(s) of action. Adv Pharmacol 37:253-297.
4. Jefford CW. 2001. Why artemisinin and certain synthetic peroxides are potent antimalarials. Implications for the mode of action. Curr Med Chem 8:1803-1826.
5. Wu Y. 2002. How might qinghaosu (artemisinin) and related compounds kill the intraerythrocytic malaria parasite? A chemist's view. Ace Chem Res 35:255-259.
6. Robert A, Coppel Y, Meunier B. 2002. Alkylation of heme by the antimalarial drug artemisinin. Chem Commun (Camb):414-415.
7. Meshnick SR. 2002. Artemisinin: Mechanisms of action, resistance and toxicity. Int J Parasitol 32: 1655-1660.
8. White N. 1999. Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci 354:739-749.
9. Tang Y, Dong Y, Vennerstrom JL. 2004. Synthetic peroxides as antimalarials. Med Res Rev 24:425-448.
10. Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FC, Chollet J, Dong Y, Dorn A, Hunziker D, Matile H, McIntosh K, Padmanilayam M, Santo Tomas J, Scheurer C, Scorneaux B, Tang Y, Urwyler H, Wittlin S, Charman WN. 2004. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 430:900-904.
11. Loftsson T, Brewster ME. 1996. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 85:1017-1025.
12. Rajewski RA, Stella VJ. 1996. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci 85:1142-1169.
13. Saenger W. 1980. Cyclodextrin inclusion compounds in research and industry. Angew Chem Int Ed Eng 19:344-362.
14. Stella VJ, Rajewski RA. 1997. Cyclodextrins: Their future in drug formulation and delivery. Pharm Res 14:556-567.
15. Stella VJ, Rao MV, Zannou EA, Zia V. 1999. Mechanisms of drug release from cyclodextrin complexes. Adv Drug Deliv Rev 36:3-16.
16. Selvidge LA, Eftink MR. 1986. Spectral displacement techniques for studying the binding of spectroscopically transparent ligands to cyclodextrins. Anal Biochem 154:400-408.
17. Rekharsky MV, Inoue Y. 1998. Complexation thermo-dynamics of cyclodextrins. Chem Rev 98:1875-1917.
18. Perry CS, Charman SA, Prankerd RJ, Chiu FCK, Scanlon MJ, Chalmers D, Charman WN. 2005. The binding interaction of synthetic ozonide antimalarials with natural and modified β-cyclodextrins. J Pharm Sci, in press.
19. Friere E, Mayorga O, Straume M. 1990. Isothermal titration calorimetry. Anal Chem 62:950A-959A.
20. Wiseman T, Williston S, Brandts J, Lin L. 1989. Rapid measurement of binding constants and heats of binding using a new titration calorimeter. Anal Biochem 179:131-137.
21. Bom A, Bradley M, Cameron K, Clark J, van Egmond J, Feilden H, MacLean E, Muir A, Palin R, Rees D, Zhang M-Q. 2002. A novel concept of reversing neuromuscular block: Chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Eng 41: 266-270.
22. Rajewski RA, Traiger G, Bresnahan J, Jaberaboansari P, Stella VJ, Thompson D. 1995. Preliminary safety evaluation of parenterally administered sulfoalkyl ether beta-cyclodextrin derivatives. J Pharm Sci 84:927-932.
23. Frijlink HW, Franssen EJF, Eissens AC, Ousting R, Lerk CF, Meijer DKF. 1991. The effect of cyclodextrins on the disposition of intravenously injected drugs in the rat. Pharm Res 18:380-384.
24. Davies BM, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
25. Brewster ME, Anderson WR, Meinsma D, Moreno D, Webb AI, Pablo L, Estes KS, Derendorf H, Bodor N, Sawchuk R, Cheung B, Pop E. 1997. Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-beta-cyclodextrin-based formulation of carbamazepine in the dog: Comparison with commercially available tablets and suspensions. J Pharm Sci 86:335-339.